|Bid||62.00 x 2900|
|Ask||62.41 x 1300|
|Day's range||62.37 - 63.41|
|52-week range||57.17 - 74.12|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||19.10|
|Forward dividend & yield||2.92 (4.74%)|
|Ex-dividend date||14 Sept 2022|
|1y target est||N/A|
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.
Every investor in Gilead Sciences, Inc. ( NASDAQ:GILD ) should be aware of the most powerful shareholder groups...